Basic Gravol Information

• INN (International Nonproprietary Name): Cinnarizine
• Brand Names Available In Canada (English): Stugeron, Cinnarizine (25 mg tab, non‑Rx)
• ATC Code: N07CA02 — cinnarizine is classified under the nervous system (N), “Other nervous system drugs” (N07), calcium‑channel blockers for vestibular disorders (CA02).
• Forms & Dosages: Oral tablet 25 mg most common; extended‑release tablets (rare) and syrup/suspension in select regions.
• Manufacturers In Canada (English): Janssen Pharmaceuticals (original), plus regional generics and international suppliers such as STADA, Hasco, Biogaran, LEK, Gedeon Richter.
• Registration Status In Canada (English): Sold online/offline; registration and OTC/Rx status vary by province.
• OTC / Rx Classification: Mostly OTC in many EU and UK markets; Canadian classification varies by province and product packaging.

Latest Research Highlights

Canadians ask whether Stugeron or Gravol works better for travel and chronic dizziness.

Recent international systematic reviews (2022–2025) and smaller Canadian observational studies show both cinnarizine and dimenhydrinate reduce motion sickness symptoms versus placebo.

Those reports note differing side‑effect profiles, with some cohorts reporting higher sedation with cinnarizine compared with dimenhydrinate.

Comparative trials to 2024 reported similar short‑term efficacy for acute motion sickness, while tolerability varied when drugs were used long term for chronic vertigo management.

For Canadians planning travel, low cost and easy access remain priorities, especially for boating and family trips.

Rural patients report limited local formularies and seasonal access that makes OTC options like gravol attractive.

Available bilingual resources (English/French) are important, and access barriers in some Indigenous communities increase the importance of planning for travel medications.

• Research Gaps: long‑term safety data for chronic use.
• Research Gaps: dosing and safety in frail elderly and those with polypharmacy.
• Research Gaps: comparative effectiveness for persistent vestibular syndromes.

Clinical Effectiveness In Canada

Patients commonly want to know which pill works fastest for nausea on a ferry or in a car.

Canadian monographs and regional summaries (2020–2024) show dimenhydrinate (Gravol) remains the first‑line OTC choice for acute motion sickness.

Cinnarizine (Stugeron) is used more for vertigo and vestibular disorders with evidence for symptomatic relief in longer‑term use.

• Drug Class → vestibular calcium‑channel blocker (cinnarizine, ATC N07CA02); antihistamine/anticholinergic (dimenhydrinate).
• Mechanism → cinnarizine reduces vestibular neuron hyperexcitability; dimenhydrinate blocks H1 receptors and has anticholinergic effects.
• Typical Effect → both reduce nausea and dizziness; cinnarizine favours vestibular stabilisation while dimenhydrinate works rapidly for acute symptoms.

Health Canada oversight requires marketed products to carry a DIN where applicable, and availability varies by province.

Provincial formularies may list alternatives rather than Stugeron, so clinicians commonly document rationale for off‑formulary prescribing.

• Strengths: Gravol has rapid onset for acute motion sickness.
• Strengths: Cinnarizine supports vestibular stabilisation in chronic management.
• Limitations: Sedation profile and fall risk in older adults.

Indications And Expanded Uses

People ask whether these medicines can help with migraine dizziness or ongoing balance problems.

Product monographs to 2025 support dimenhydrinate for prophylaxis and treatment of motion sickness and cinnarizine for vertigo and vestibular disorders.

Off‑label uses reported in practice include migraine‑associated dizziness and persistent postural‑perceptual dizziness, though evidence is limited.

• Approved Indications: motion sickness (dimenhydrinate), vertigo/vestibular disorders (cinnarizine).
• Common Off‑Label Uses: migraine‑related dizziness, PPPD (clinician judgement required).

Cultural context matters for travellers from remote northern communities and Indigenous patients where isolation increases stakes for prophylaxis and bilingual labelling is important.

Age note: cinnarizine is not recommended under 5 years.

Composition And Brand Landscape

Patients often ask what’s in the tablet and who makes it.

Active ingredients covered here are cinnarizine (INN) and dimenhydrinate (Gravol).

Stugeron is marketed as cinnarizine 25 mg tablets and is available in Canada with English and French packaging in some supplies.

• Manufacturer Landscape: Janssen (original), STADA, Hasco, Biogaran, LEK, Gedeon Richter, regional generics.
• Canadian Availability: Gravol (dimenhydrinate) is widely stocked at major chains; Stugeron is less ubiquitous and may be ordered online or sourced in select pharmacies.
• Advice: check the Drug Identification Number (DIN) on Canadian packaging and bilingual labelling in Quebec and New Brunswick.

Definitions: INN = International Nonproprietary Name; DIN = Drug Identification Number; ATC = Anatomical Therapeutic Chemical code.

Contraindications And Special Precautions

Safety is the top concern for older adults and pregnant people.

Product literature lists absolute contraindications for cinnarizine including allergy to cinnarizine or excipients, porphyria, severe hepatic impairment, and pregnancy/breastfeeding avoidance unless absolutely necessary.

Dimenhydrinate (Gravol) contraindications include severe asthma and caution with monoamine oxidase inhibitors.

• Absolute Contraindications: allergy to active ingredient or excipients; porphyria; severe hepatic impairment; pregnancy and breastfeeding for cinnarizine.
• Relative Contraindications: Parkinson’s disease (cinnarizine may worsen parkinsonism); elderly with cognitive impairment; significant liver or kidney disease; concurrent alcohol or CNS depressants.

Community pharmacists at chains like Shoppers Drug Mart and Rexall should screen for interactions and high‑risk groups before sale.

Pharmacist Screening Checklist: current medications, pregnancy status, age, known liver disease, Parkinson’s disease, use of opioids or cannabis, and planned activities (driving, boating).

Data highlight: seniors report increased confusion and sedation; counsel on fall risk and avoiding driving until response is known.

Discuss pregnancy and breastfeeding risks in shared decision‑making and provide information in the patient’s preferred language where possible.

Dosage Guidelines

People often ask how long before travel they should take a tablet.

Standard cinnarizine dosages: 25 mg tablets are common; take 25 mg two hours before travel and repeat every eight hours if needed for motion sickness.

For vertigo, cinnarizine is commonly used as 25 mg three times daily (total 75 mg/day).

Children: cinnarizine is not recommended under 5 years; ages 5–12 commonly use 12.5 mg two to three times daily.

Dimenhydrinate dosing differs; typical adult OTC dosing is 50–100 mg every 4–6 hours as needed.

• Dosing By Indication: prophylaxis for motion sickness versus maintenance therapy for chronic vertigo.
• Elderly Adjustments: reduce dose and monitor for sedation, confusion, and falls.
• Hepatic/Renal Cautions: cinnarizine is primarily metabolized by the liver (CYP2D6); reduce dose with hepatic impairment.

Pharmacists should document counselling including dose timing and missed dose instructions, and provide bilingual materials when requested.

Interactions Overview

Patients often wonder whether these pills are safe with antidepressants, benzodiazepines, or alcohol.

Cinnarizine interacts additively with other CNS depressants and may be affected by CYP2D6 inhibitors that raise plasma levels.

Dimenhydrinate has anticholinergic interactions and causes additive sedation with opioids, benzodiazepines, and alcohol.

• High‑Risk Interactions: CNS depressants (opioids, benzodiazepines), other anticholinergics, MAOIs (caution with dimenhydrinate), and CYP2D6 inhibitors (cinnarizine).
• Patient Advice: avoid alcohol and recreational cannabis while taking these medicines because sedation and confusion can increase.

Pharmacy chains in Canada commonly screen for these interactions and provide counselling at point of sale.

Special monitoring is needed for patients in remote Indigenous communities who may have limited access to follow‑up care.

Cultural Perceptions And Patient Habits

Many Canadians consider Gravol the default travel pill and expect it at checkout aisles.

Forum analyses and surveys (2020–2024) show Gravol is commonly perceived as the go‑to option, while Stugeron (cinnarizine) is less familiar outside specialist clinics.

Patients frequently report sedation and next‑day drowsiness as the main downsides.

• Common Behaviours: pre‑travel dosing, combining with alcohol or cannabis, seeking non‑drug alternatives such as acupressure bands.
• Rural Concerns: inconsistent stock at small pharmacies and longer travel to refill prescriptions.
• Indigenous Context: local health centres may stock different formularies and bilingual information is important.

Many travellers prefer non‑sedating options when they plan to drive or boat, and demand for such options shapes local pharmacy stock decisions.

Availability And Pricing Patterns

Patients want a quick answer: where can I buy Gravol or Stugeron and how much will it cost?

Market data to 2024 show Gravol (dimenhydrinate) is widely available OTC at major retailers across Canada, while Stugeron availability is patchier and often found online or at selected pharmacies.

Generics of dimenhydrinate are commonly cheaper; Stugeron imported or branded packs may cost more per dose.

• Buying Channels: in‑store retail, provincial online pharmacy portals, online importers (check DIN and supplier).
• Cross‑Border Note: cinnarizine is less available in US markets; dimenhydrinate equivalents like Dramamine are common in the US but branding and formulations may differ.
• Provincial Coverage: most provincial drug plans do not routinely reimburse OTC Gravol; check Ontario Drug Benefit, BC PharmaCare, and RAMQ for exceptions or special authorizations.

For convenience, gravol is available without a prescription from this online pharmacy, with discreet delivery to Canada (English) in 5–14 days.

Advice: always check the DIN and confirm bilingual labelling for Quebec and New Brunswick purchases.

Comparable Medicines And Preferences

Patients often ask for alternatives when sedation is a concern.

Common alternatives in Canada include dimenhydrinate (Gravol), meclizine, promethazine (prescription), and transdermal scopolamine patches for sea travel.

Betahistine is used for Ménière’s disease in some jurisdictions but is not universally available OTC in Canada.

• Gravol: OTC, effective for acute symptoms, can be sedating.
• Meclizine: sometimes less sedating for some patients; availability varies.
• Scopolamine Patch: prescription option for prolonged sea travel; useful when non‑oral dosing is preferred.
• Cinnarizine: useful for chronic vestibular stabilisation; caution in parkinsonism.

For chronic vertigo consider vestibular rehabilitation in addition to or instead of long‑term pharmacotherapy, and document patient preferences including language needs.

Frequently Asked Questions

• Q: Is Gravol the same as Stugeron?
  A: No.
  Gravol is dimenhydrinate and Stugeron is cinnarizine; they work differently.
• Q: Can I drive after taking Gravol or Stugeron?
  A: Both can cause sedation.
  Avoid driving until you know how the medicine affects you, especially if you are older.
• Q: Are these covered by provincial drug plans?
  A: OTC Gravol is generally not on standard formularies.
  Check ODB, BC PharmaCare, and RAMQ or apply for exceptional access where needed.
• Q: Can pregnant people use them?
  A: Cinnarizine is generally avoided in pregnancy and breastfeeding unless necessary.
  Gravol is sometimes used under clinician guidance; consult your health care provider.
• Q: What about children?
  A: Age limits vary.
  Cinnarizine is not recommended under 5 years and dosing for children differs; follow product labels and pharmacist advice.

Always verify the DIN and bilingual labelling on the package before purchase.

Guidelines For Proper Use

Travellers want a simple checklist to avoid nausea at 2 a.m. on a ferry.

• Take the prophylactic dose 1–2 hours before travel as recommended on the product label.
• Avoid alcohol and recreational cannabis while taking these medications due to increased sedation risk.
• Trial the medicine at home first to assess sedation before driving or boating.
• Use non‑drug measures as adjuncts: sit facing forward, look at the horizon, use acupressure bands.

Pharmacists should document counselling, check the DIN, screen for interactions, and provide bilingual leaflets where requested.

For Indigenous and remote communities consider telepharmacy follow‑up and culturally safe counselling.

Always check the product’s DIN and Health Canada monograph before recommending prolonged use.

Delivery Across Canada (English)